Patent: 9,694,053
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,694,053
Title: | Dual GLP-1/glucagon receptor agonists |
Abstract: | The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. |
Inventor(s): | Haack; Torsten (Frankfurt am Main, DE), Wagner; Michael (Frankfurt am Main, DE), Henkel; Bernd (Frankfurt am Main, DE), Stengelin; Siegfried (Frankfurt am Main, DE), Evers; Andreas (Frankfurt am Main, DE), Bossart; Martin (Frankfurt am Main, DE), Kadereit; Dieter (Frankfurt am Main, DE) |
Assignee: | SANOFI (Paris, FR) |
Application Number: | 14/569,387 |
Patent Claims: | see list of patent claims |
Details for Patent 9,694,053
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | 10/28/1982 | ⤷ Try a Trial | 2033-12-13 |
Eli Lilly And Company | HUMULIN R U-500 | insulin human | Injection | 018780 | 12/29/2015 | ⤷ Try a Trial | 2033-12-13 |
Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | 08/06/1998 | ⤷ Try a Trial | 2033-12-13 |
Eli Lilly And Company | HUMULIN R U-500 | insulin human | Injection | 018780 | 03/31/1994 | ⤷ Try a Trial | 2033-12-13 |
Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | 05/25/2018 | ⤷ Try a Trial | 2033-12-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |